Page 1

Recursion . Recursion Reports First Quarter 2021 Financials and Provides Business Updates May 12 , 2021 - Strengthened balance sheet with the completion of a successful IPO -Purchased , built , and activated BioHive - 1 , reportedly the 58th most powerful supercomputer in the world , to accelerate our drug discovery process - Continued development of internal pipeline and partnership programs remain on track - Promoted Ron Alfa M.D. , Ph.D. to Senior Vice President of Research , to assume the responsibilities of outgoing Chief Scientific Officer Sharath Hegde , Ph.D. and further strengthen our commitment to inferential search SALT LAKE CITY , May 12 , 2021 / PRNewswire / -- Recursion Pharmaceuticals , Inc. ( Nasdaq : RXRX ) , a clinical - stage biotechnology company decoding biology by integrating technological innovations across biology , chemistry , automation , data science , and engineering , today reported financial results for the first quarter of 2021 and provided business updates . " We are thrilled to have led Recursion through a successful IPO process which garnered support from new and existing healthcare and technology investors and better capitalized the company's mission of decoding biology to radically improve lives , " said Recursion Co - Founder and CEO Chris Gibson Ph.D. He continued , " We are excited about Recursion's continued foray into inferential search , how that approach has quickly added many new programs to our portfolio in a short time , and how our new supercomputer , BioHive - 1 , will enable faster training and iteration of our machine learning algorithms and the ability to train on the totality of our nearly 8 petabytes of relatable biological data . And finally , we continue to make strides expanding , advancing , and executing on our pipeline of potential new medicines , including our four clinical stage programs and our first new chemical entity now headed towards clinical development . " Recursion finished the first quarter of 2021 with a portfolio of 4 clinical stage programs , 4 preclinical programs , 4 late discovery programs , and 25 early discovery programs , for a total of 37 research and development programs . Additionally , Recursion continued scaling the total number of executed phenomic experiments to over 67 million , the size of its total dataset to nearly 8 petabytes , and the number of biological inferences to over 92 billion . We accomplished this by utilizing a cellular library of 36 cell types , an in - house chemical library of over 706 thousand compounds , an in silico library of over 12 billion chemical scaffolds , and a growing team of more than 200 Recursionauts that is balanced between life scientists and computational and technical experts . Summary of Business Highlights • Clinical Programs o Familial adenomatous polyposis ( REC - 4881 ) : We plan to initiate a Phase 2 , randomized , double - blind , placebo- controlled study to evaluate efficacy and safety of REC - 4881 in classical FAP patients within the next 4 to 5 quarters . • GM2 gangliosidosis ( REC - 3599 ) : We are generating additional pharmacodynamic data in an animal model of GM2 in anticipation of enrolling the first patient in an open - label Phase 2 trial in the next 4 to 5 quarters . • Neurofibromatosis type 2 ( REC - 2282 ) : The protocol has been updated based on scientific advice from the MHRA and FDA feedback from the special protocol assessment ( SPA ) . We expect to enroll the first patient in an adaptive Phase 2/3 , randomized , multicenter study within the next 4 to 5 quarters . o Cerebral cavernous malformation ( REC - 994 ) : We finalized the Phase 2 protocol and submitted it to the FDA . Subject to completion of all required CMC steps , we expect to enroll the first patient in a Phase 2 , double - blind , placebo - controlled , safety , tolerability and exploratory efficacy study within the next 4 to 5 quarters . • Notable Preclinical Programs o Clostridium difficile colitis ( REC - 163964 , REC - 164014 , REC - 164067 ) : We completed exploratory , non - clinical , safety studies with three lead molecules to enable selection of a development candidate . o Immune checkpoint resistance in STK11 - mutant NSCLC : We completed dose - optimization studies of REC - 64151 that supported efficacy in rodent models at exposures achievable in humans . • Notable Late Discovery Programs o Neuroinflammation : This program is currently in the lead - optimization phase . The project has made progress in optimization of potency and pharmacokinetics of molecules in our lead series . o Batten disease : The program is currently in the lead - optimization phase . The project has made progress in optimization of potency and pharmacokinetics of molecules in our lead series . o Charcot - Marie - Tooth type 2A : The chemistry strategy has been constructed and relevant biochemical and cellular orthogonal assays are being developed . o Oncology - small molecule MYC Inhibitors : We have now confirmed that several molecules from multiple series